Characterization of neurotensin(6–13) from an hepatic fibrolamellar carcinoma

doi:10.1016/0196-9781(91)90152-F

Peptides

Volume 12, Issue 4, July–August 1991, Pages 887-892

https://doi.org/10.1016/0196-9781(91)90152-F Get rights and content

Abstract

Neurotensin(6–13) has been isolated and sequenced as the major form of neurotensin-like immunoreactivity (NTLI) in a human hepatic fibrolamellar carcinoma. Circulating NTLI in the patient, especially C-terminal, was very high. In additional studies, NT(6–13) was synthesized and compared with the purified tumor NTLI by HPLC analysis and by testing stability in plasma in vitro. These methods confirmed that the tumor NTLI was identical to NT(6–13). Since the metabolic clearance rate of synthetic NT(6–13) in sheep was 30-fold higher than NT(1–13), it suggests that the elevated plasma levels are the result of impaired clearance and/or markedly elevated production.

References (28)

M.A. Berman
Fibrolamellar carcinoma of the liver: An immunohistochemical study of nineteen cases and a review of the literature
Hum. Pathol.
(1988)
R. Carraway et al.
Precursor forms of neurotensin (NT) in cat: Processing with pepsin yields NT-(3–13) and NT-(4–13)
Regul. Pept.
(1987)
N.A. Collier et al.
Neurotensin secretion by fibrolamellar carcinoma of the liver
Lancet
(1984)
Y.C. Lee et al.
Chromatographic characterization of neurotensin-like immunoreactivity in plasma and tissue extracts from hepatoma patients
Clin. Chim. Acta
(1985)
J.R. McDermott et al.
Mechanisms of neurotensin degradation by rat brain peptidases
Regul. Pept.
(1982)
S.P. Mitra et al.
Canine neurotensin, neurotensin^6–13 and neuromedin N: Primary structures and receptor activity
Regul. Pept.
(1990)
M.H. Mogard et al.
Isolation and characterization of a neurotensin-like decapeptide from a canine upper small intestinal extract
Regul. Pept.
(1986)
T.W. Moody et al.
Neurotensin is produced by and secreted from classic small cell lung cancer cells
Life Sci.
(1985)
C. Shaw et al.
Catabolism of neurotensin in the epithelial layer of porcine small intestine
Biochim. Biophys. Acta
(1987)
A. Shulkes et al.
Neurotensin metabolism in the rat: Contribution of the kidney
Peptides
(1987)

R.A. Skidgel et al.

Hydrolysis of substance P and neurotensin by converting enzyme and neutral endopeptidase

Peptides

(1984)

A.M. Blackburn et al.

Pancreatic tumors produce neurotensin

J. Clin. Endocrinol. Metab.

(1981)

P.K. Buamah et al.

A pleomorphic hepatocellular carcinoma with biochemical features of fibrolamellar hepatocellular carcinoma

J. Surg. Oncol.

(1986)

R. Carraway et al.

Characterization of radioimmunoassayable neurotensin in the rat: Its differential distribution in the central nervous system, small intestine and stomach

J. Biol. Chem.

(1976)

Cited by (10)

The potential use of the neurotensin high affinity receptor 1 as a biomarker for cancer progression and as a component of personalized medicine in selective cancers
2011, Biochimie
Citation Excerpt :
The gene encoding NTS is also spatio-temporally regulated during human development with a transient expression in the fetal liver, colon, pancreas, and stomach, suppressed in the adult within the first weeks of birth [101]. Re-expression has been reported in the rare fibrolamellar hepatic carcinomas [102,103], in one sample of hepatocellular cancer [104], and in approximately 25% of resected colon cancers [105]. The pathological NTS expression in ectopic tissues suggested modifications in the regulatory mechanisms of the NTS gene.
A growing challenge in medicine today, is the need to improve the suitability of drug treatments for cancer patients. In this field, biomarkers have become the “flags” to provide additional information in tumor biology. They are a relay between the patient and practitioner and consequently, aid in the diagnosis, providing information for prognosis, or in some cases predicting the response to specific therapies. In addition to being markers, these tumor “flags” can also be major participants in the process of carcinogenesis.
Neurotensin receptor 1 (NTSR1) was recently identified as a prognosis marker in breast, lung, and head and neck squamous carcinomas. Neurotensin (NTS) was also shown to exert numerous oncogenic effects involved in tumor growth and metastatic spread. These effects were mostly mediated by NTSR1, making the NTS/NTSR1 complex an actor in cancer progression. In this review, we gather information on the oncogenic effects of the NTS/NTSR1 complex and its associated signaling pathways in order to illuminate its significant role in tumor progression and its potential as a biomarker and a therapeutic target in some tumors.
Adult-type hepatocellular carcinoma in the center of a fibrolamellar hepatocellular carcinoma
2002, Human Pathology
Citation Excerpt :
Answering this question is of significance insofar as it is still not settled whether the pathways leading to FL-HCC are similar or clearly different from those resulting in adult-type HCC, even though FL-HCC is, apart from its distinct morphology and predominant manifestation age, strikingly different from ordinary HCC in terms of several other aspects. These aspects include the development in noncirrhotic livers, a better prognosis,8 rarity of high-titer serum alpha-fetoprotein, neuroendocrine features,5 aromatase activity of tumor cells,6 marked expression of the invasion-related membrane protein CD44,10 a diploid DNA pattern,11 and nearly normal karyotypes, contrasting with the numerous aberrations detected in other HCCs.12 In the event that tumor components resembling FL-HCC are detectable within an adult-type HCC, it is difficult to judge by conventional histology alone whether such sclerosing lesions in fact represent bona fide FL-HCC or rather a stromal-rich subline emerging in an adult-type HCC, the latter tumors being well known for their heterogeneity in composition, also with respect to matrix production.
A large hepatic tumor was detected in the noncirrhotic liver of a 27-year-old female patient. The tumor was radiologically characterized by a peripheral mass encircling a central ovoid tumor, and was resected by an extended right hemihepatectomy. Histologic examination revealed that the peripheral and major component of the tumor represented a fibrolamellar hepatocellular carcinoma, whereas the central, well-demarcated tumor was a less well-differentiated adult-type hepatocellular carcinoma completely encircled by the former. Cells of the peripheral tumor mass abundantly expressed cytokeratin-7, typically present in the fibrolamellar variant, whereas no cytokeratin-7 immunoreactivity was found in the central tumor. To our knowledge, this is the first reported case of a not admixed but clearly separated evolution of these 2 histologic patterns within the same tumor, and suggests that the 2 types of hepatocellular carcinoma may share a common pathogenic pathway. HUM PATHOL 33:765-769. Copyright 2002, Elsevier Science (USA). All rights reserved.
Induction of the neurotensin (NT) gene in PC12 cells gives rise to NT precursor (∼88%), NT(3-13)-like peptide (∼10%), and NT (∼2%)
1993, Peptides
Neurotensin (NT) is coexpressed with catecholamines in sympathetic neurons and adrenal chromaffin cells. A pheochromocytoma PC12 cell line can also be induced to express the NT gene and produce immunoreactive NT. In the present study, NT mRNA was quantified under various hormonal conditions and NT precursor synthesis rates were determined by pulse labeling and immunoprecipitation. In addition, NT precursor and NT-related products were measured using RIA and were characterized using HPLC and Sephadex chromatography. Neurotensin mRNA, NT precursor synthesis, and NT precursor/product levels were correlated. Surprisingly, NT appeared to be a minor product, both in cells and media: NT precursor (∼88%), NT(3–13)-like peptide (∼10%), and NT(∼2%). Neurotensin added to cultures was not converted to NT(3–13). Treatment of cells with 60 mM KCl or various secretagogues induced Ca²⁺-dependent release of NT precursor, NT(3–13), and NT in proportion to their cellular contents. These results suggest a) that NT precursor processing in induced PC12 cells was much slower than NT precursor synthesis, b) that NT(3–13) was a major product and NT a minor one, and c) that NT precursor and its products were stored within secretory vesicles.
Neurotensin as a source of cyclic AMP and co-mitogen in fibrolamellar hepatocellular carcinoma
2019, Oncotarget
Fibrolamellar Hepatocellular Carcinoma: Mechanistic Distinction From Adult Hepatocellular Carcinoma
2016, Pediatric Blood and Cancer
Endocrine gene neurotensin: Molecular mechanisms and a model of intestinal differentiation
2002, World Journal of Surgery

View all citing articles on Scopus

View full text

Characterization of neurotensin(6–13) from an hepatic fibrolamellar carcinoma

Abstract

Hum. Pathol.

Regul. Pept.

Lancet

Clin. Chim. Acta

Regul. Pept.

Regul. Pept.

Regul. Pept.

Life Sci.

Biochim. Biophys. Acta

Peptides

Peptides

Pancreatic tumors produce neurotensin

J. Clin. Endocrinol. Metab.

A pleomorphic hepatocellular carcinoma with biochemical features of fibrolamellar hepatocellular carcinoma

J. Surg. Oncol.

Characterization of radioimmunoassayable neurotensin in the rat: Its differential distribution in the central nervous system, small intestine and stomach

J. Biol. Chem.